Skip to main content
. 2022 Apr 19;3(4):100607. doi: 10.1016/j.xcrm.2022.100607

Figure 5.

Figure 5

Temporal trajectories of plasma NfL in presymptomatic individuals and individuals with MCI who phenoconverted according to mutation status

Shown, according to mutation status, are longitudinal NfL concentrations for 23 mutation carriers who phenoconverted (i.e., 14 from presymptomatic to symptomatic and nine from MCI to bvFTD). For five individuals, plasma NfL was not available from the follow-up visit at which their diagnosis changed; these individuals are marked by a white circle partially shaded in black for clinically normal individuals later diagnosed with MCI or by a gray square partially shaded in black for a patient with MCI subsequently diagnosed with bvFTD. NfL in plasma samples was measured in duplicate, and mean concentrations are shown on the base 10 logarithm scale. CN, clinically normal; PD, Parkinson’s disease.